CSPC Innovation Pharmaceutical

CSPC Innovation Pharmaceutical is a leading Chinese biopharmaceutical company and a key subsidiary of the CSPC Pharmaceutical Group. Historically a dominant global supplier of caffeine and functional food additives, the company has strategically pivoted toward the development of innovative biologics and advanced therapeutics. Following the acquisition of CSPC Megalith Biopharmaceutical, its pipeline now features a robust collection of antibody-drug conjugates (ADCs), monoclonal antibodies, and mRNA-based vaccines. The company's lead programs target high-impact indications in oncology, such as gastric and breast cancers, as well as metabolic diseases like diabetes and obesity. CSPC Innovation Pharmaceutical maintains integrated capabilities spanning from early-stage R&D to large-scale GMP manufacturing. It is publicly listed on the Shenzhen Stock Exchange and actively engages in global licensing agreements to expand its international footprint.